Preclinical studies suggest that reduction of prolactin levels via treatment with dopamine D2 agonists (bromocriptine and dihydroergocryptine) reduces severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS [16-19]. Here, PRL is linked to experimental autoimmune encephalomyelitis.